Effects of Tamoxifen on Cardiovascular Risk Factors in Postmenopausal Women
Authors: Richard R. Love, Donald A. Wiebe, Polly A. Newcomb, Linda Cameron, Howard Leventhal, V. Craig Jordan, Jan Feyzi, David L. DeMets
Journal: Annals of Internal Medicine (1991)

Article1 December 1991Effects of Tamoxifen on Cardiovascular Risk Factors in Postmenopausal WomenRichard R. Love, MD, Donald A. Wiebe, MD, Polly A. Newcomb, PhD, Linda Cameron, PhD, Howard Leventhal, PhD, V. Craig Jordan, PhD, DSc, Jan Feyzi, MS, David L. DeMets, PhDRichard R. Love, MD, Donald A. Wiebe, MD, Polly A. Newcomb, PhD, Linda Cameron, PhD, Howard Leventhal, PhD, V. Craig Jordan, PhD, DSc, Jan Feyzi, MS, David L. DeMets, PhDAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-115-11-860 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptObjective: To determine the effects of tamoxifen on risk factors for cardiovascular disease in disease-free postmenopausal women.Design: Double-blind, placebo-controlled, randomized 2-year clinical trial.Setting: University health sciences center. Patients: Clinically postmenopausal women (140) with a diagnosis of axillary node-negative breast cancer, who were disease-free by laboratory and clinical evaluations.Measurements: Levels of total cholesterol, high-density lipoprotein (HDL) cholesterol, triglycerides, apolipoprotein A-I, apolipoprotein B, glucose, weight, blood pressure, and reported exercise and work activity were measured.Main Results: Postmenopausal women receiving tamoxifen were evaluated at 3- or 6-month intervals during a 2-year assessment period and showed a mean decrease of 12% in total cholesterol levels (at 24 months - 0.672 mmol/L; 95% Cl, - 0.839 to - 0.505 mmol/L) and a mean decrease of 20% in calculated low-density lipoprotein (LDL) cholesterol levels (at 24 months, - 0.725 mmol/L; 95% Cl, - 0.868 to - 0.583 mmol/L) (P < 0.001). Women with greater baseline cholesterol levels had greater decreases with tamoxifen treatment. Levels of HDL cholesterol decreased in patients treated with tamoxifen, but this decrease was only statistically significant at one of five measurement times. Apolipoprotein A-I levels increased significantly at the two time points at which it was measured (P = 0.02), and apolipoprotein B levels decreased significantly at these times (P < 0.01) in patients treated with tamoxifen. Plasma glucose levels, reported exercise and work activity, reported smoking, weight, and systolic and diastolic blood pressures did not change with treatment.Conclusion:During 2 years of treatment, tamoxifen showed generally favorable effects on the lipid and lipoprotein profile of treated postmenopausal women. These effects may partially explain the decrease in adverse events and in mortality related to coronary heart disease seen in patients receiving adjuvant tamoxifen treatment....References1. LernerJordan LV. Development of antiestrogens and their use in breast cancer: eighth Cain memorial award lecture. Cancer Res. 1990;50:4177-89. MedlineGoogle Scholar2. Love R. Tamoxifen therapy in primary breast cancer: biology, efficacy, and side effects. J Clin Oncol. 1989;7:803-15. CrossrefMedlineGoogle Scholar3. . Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women. N Engl J Med. 1988;319:1681-92. CrossrefMedlineGoogle Scholar4. FisherBrownWolmarkRedmondWickerhamWittliff BANCDJ. Prolonging tamoxifen therapy for primary breast cancer. Findings from the National Surgical Adjuvant Breast and Bowel Project clinical trial. Ann Intern Med. 1987;106:649-54. LinkGoogle Scholar5. . Adjuvant tamoxifen in the management of operable breast cancer: the Scottish Trial. Lancet. 1987;2:171-5. MedlineGoogle Scholar6. FalksonGrayWolbergGillchristHarrisTormey HRWKJD. Adjuvant trial of 12 cycles of CMFPT followed by observation or continuous tamoxifen versus four cycles of CMFPT in postmenopausal women with breast cancer: an Eastern Cooperative Oncology Group phase III study. J Clin Oncol. 1990;8:599-607. CrossrefMedlineGoogle Scholar7. BoccardoRubagottiBruzziCappelliniIsolaNenci FAPMGI. Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, estrogen receptor-positive breast cancer patients: results of a multicentric Italian study. J Clin Oncol. 1990;8:1310-20. CrossrefMedlineGoogle Scholar8. Jordan V. Chemosuppression of breast cancer with tamoxifen: laboratory evidence and future clinical investigations. Cancer Invest. 1988;6:589-95. CrossrefMedlineGoogle Scholar9. Love R. Prospects for antiestrogen chemoprevention of breast cancer. J Natl Cancer Inst. 1990;82:18-21. CrossrefMedlineGoogle Scholar10. LoveNewcombWiebeSurawiczJordanCarbone RPDTVP. Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer. J Natl Cancer Inst. 1990;82:1327-32. CrossrefMedlineGoogle Scholar11. LoveCameronConnellLeventhal RLBH. Symptoms associated with tamoxifen treatment in post-menopausal women. Arch Intern Med 1991;151:1842-7. CrossrefMedlineGoogle Scholar12. FriedewaldLevyFredrickson WRD. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502. CrossrefMedlineGoogle Scholar13. RifaiKing NM. Immunoturbidimetric assays of apolipoproteins A, A-I, A-II, and B in serum. Clin Chem. 1986;32:957-61. CrossrefMedlineGoogle Scholar14. CurmeColumbusDappenEderFellowsFigueras HRGTWJ. Multilayer film elements for clinical analysis: general concepts. Clin Chem. 1978;24:1335-42. CrossrefMedlineGoogle Scholar15. WeiLachin LJ. Two-sample asymptomically distribution-free test for incomplete multivariate observations. Journal of the American Statistical Association. 1984;79:653-61. CrossrefGoogle Scholar16. PowlesHardyAshleyFarringtonCosgroveDavey TJSGDJ. A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer. Br J Cancer. 1989;60:126-31. CrossrefMedlineGoogle Scholar17. BruningBonfrerHartde Jong-BakkerLindersvan Loon PJAMDJ. Tamoxifen, serum lipoproteins and cardiovascular risk. Br J Cancer. 1988;58:497-9. CrossrefMedlineGoogle Scholar18. BertelliPronzatoAmorosoCusimanoConteMontagna GPDMPG. Adjuvant tamoxifen in primary breast cancer: influence on plasma lipids and antithrombin III levels. Breast Cancer Res Treat. 1988;12:307-10. CrossrefMedlineGoogle Scholar19. Sedlacek S. Estrogenic properties of tamoxifen on serum lipids in postmenopausal women with breast cancer [Abstract]. Breast Cancer Res Treat. 1989;14:153. Google Scholar20. BagdadeWolterSubbaiahRyan JJPW. Effects of tamoxifen treatment on plasma lipids and lipoprotein lipid composition. J Clin Endocrinol. Metab. 1990;70:1132-5. CrossrefMedlineGoogle Scholar21. SchapiraKumarLyman DMG. The effect of tamoxifen therapy on serum cholesterol [Abstract]. Proceedings of the American Society for Clinical Oncology. 1990;9:49. Google Scholar22. SkipskiBarclayBarclayFetzerGoodArchibald VMRVJF. Lipid composition of human serum lipoproteins. Biochem J. 1967;104:340-52. CrossrefMedlineGoogle Scholar23. BushBarrett-ConnorCowanCriquiWallaceSuchindran TELMRC. Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. Circulation. 1987;75:1102-9. CrossrefMedlineGoogle Scholar24. LoveSurawiczWilliams RTE. Antithrombin III, fibrinogen, and platelet number changes with adjuvant tamoxifen therapy. Arch Intern Med. 1991 [In press] Google Scholar25. Stewart H. Consensus Conference on Adjuvant therapy in node negative breast cancer. Washington, DC, 18 June 1990. Google Scholar26. ManolioPearsonWengerBarrett-ConnorPayneHarlan TTNEGW. Cholesterol and heart disease in older persons and women: overview of an NHLBI workshop. Am J Epidemiol. 1991; [In press]. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: From the Cancer Prevention and Breast Programs, University of Wisconsin Clinical Cancer Center, Madison, Wisconsin. For current author addresses, see end of text. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byClinical practice to address tamoxifen nonadherenceSerendipity in the search for "morning-after pills" led to clomiphene for the induction of ovulationG1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancerCardiometabolic Effects of Endocrine Treatment of Estrogen Receptor–Positive Early Breast CancerThe SERM Saga, Something from Nothing: American Cancer Society/SSO Basic Science LectureA Novel Strategy to Improve Women's Health: Selective Estrogen Receptor ModulatorsAssociation between tamoxifen use and acute myocardial infarction in women with breast cancerEfficacy of Complementary Therapies in the Quality of Life of Breast Cancer SurvivorsPrimary Prevention of Breast CancerToxicity of Extended Adjuvant Therapy With Aromatase Inhibitors in Early Breast Cancer: A Systematic Review and Meta-analysisClinically Relevant Physical Benefits of Exercise Interventions in Breast Cancer SurvivorsIs There a Role for Raloxifene and Tamoxifen for the Prevention of Breast Cancer?The molecular, cellular and clinical consequences of targeting the estrogen receptor following estrogen deprivation therapyTamoxifen Treatment and the Reduced Risk of Hyperlipidemia in Asian Patients With Breast Cancer: A Population-Based Cohort StudyExercise Prevention of Cardiovascular Disease in Breast Cancer SurvivorsThe evolution of nonsteroidal antiestrogens to become selective estrogen receptor modulatorsStock identification of neon flying squid (Ommastrephes bartramii) in the North Pacific Ocean on the basis of beak and statolith morphologyAssociation of Aromatase Inhibitors With Coronary Heart Disease in Women With Early Breast CancerAssociation of Tamoxifen Use and Reduced Cardiovascular Events Among Asian Females With Breast CancerEndocrine Therapy for Breast CancerTamoxifen inhibits macrophage FABP4 expression through the combined effects of the GR and PPARγ pathwaysEffect of chronic administration of tamoxifen and/or estradiol on feeding behavior, palatable food and metabolic parameters in ovariectomized ratsExtended adjuvant endocrine therapy in hormone dependent breast cancer: The paradigm of the NCIC-CTG MA.17/BIG 1–97 trialLong-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trialThe Wisconsin Story in the 1980s: Discovery of Target Site-Specific Estrogen ActionEstrogen-Mediated Mechanisms to Control the Growth and Apoptosis of Breast Cancer CellsCancer Therapy–Induced Cardiac Toxicity in Early Breast CancerResearch Resource: Transcriptional Profiling in a Cellular Model of Breast Cancer Reveals Functional and Mechanistic Differences Between Clinically Relevant SERM and Between SERM/Estrogen ComplexesBreast Cancer Chemoprevention: Current Approachesand Future DirectionsManganese superoxide dismutase: beyond life and deathEvolution of Selective Estrogen and Androgen Receptor Modulators: Status of Current Therapy and New Drug DevelopmentThe St. Gallen Prize Lecture 2011: Evolution of long-term adjuvant anti-hormone therapy: consequences and opportunitiesToxicity of Adjuvant Endocrine Therapy in Postmenopausal Breast Cancer Patients: A Systematic Review and Meta-analysisManagement of Bone Disease in Patients Undergoing Hormonal Therapy for Breast CancerEffect of tamoxifen on the coronary vascular reactivity of spontaneously hypertensive female ratsThe PEARL trial: lasofoxifene and incidence of fractures, breast cancer and cardiovascular events in postmenopausal osteoporotic womenEffect of tamoxifen on lipid metabolizing enzymes in women with breast cancerLasofoxifene and Cardiovascular Events in Postmenopausal Women With OsteoporosisSERMs: Progress and future perspectivesCaring for the Breast Cancer Survivor: A Guide for Primary Care PhysiciansImpact of triglycerides on lipid and lipoprotein biology in womenHormonal therapies in Breast and Prostate Cancer: Effects on Bone and the Role of BisphosphonatesCare of the Cancer Survivor: Metabolic Syndrome after Hormone-Modifying TherapyExpressions of Vascular Endothelial Growth Factor and Nitric Oxide Synthase III in the Thyroid Gland of Ovariectomized Rats Are Upregulated by Estrogen and Selective Estrogen Receptor ModulatorsA woman's heartBreast-Cancer Prevention with AntiestrogensThe BreastPrimary Prevention of Breast CancerOptimizing aromatase inhibitor integration into initial treatment strategies in postmenopausal women with hormone-receptor-positive early breast cancerTamoxifen for early breast cancerThe 38th David A. Karnofsky Lecture: The Paradoxical Actions of Estrogen in Breast Cancer—Survival or Death?The Rise of Raloxifene and the Fall of Invasive Breast CancerMenopausal Health After Breast CancerCost-effectiveness analysis of anastrozole vs tamoxifen in adjuvant therapy for early stage breast cancer in the United Kingdom: the 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen alone or in combination) trialBreast cancer bone metastasis and current small therapeuticsTamoxifenMolecular Pharmacology of Estrogen and Progesterone ReceptorsPostmenopausal Breast SurveillanceExploiting the apoptotic actions of oestrogen to reverse antihormonal drug resistance in oestrogen receptor positive breast cancer patientsDevelopment and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancerThe Cardiovascular Effects of Selective Estrogen Receptor ModulatorsOptimising endocrine approaches for the chemoprevention of breast cancerEffects of adjuvant aromatase inhibitor therapy on lipid profilesBone safety of aromatase inhibitors versus tamoxifenThe novel vitamin D analog ZK191784 as an intestine-specific vitamin D antagonistLigand binding by estrogen receptor beta attached to nanospheres measured by fluorescence correlation spectroscopyTamoxifen Treatment After Adjuvant Chemotherapy Has Opposite Effects on Bone Mineral Density in Premenopausal Patients Depending on Menstrual StatusCoronary Heart Disease and Stroke with Aromatase Inhibitor, Tamoxifen, and Menopausal Hormone Therapy UseTamoxifen (ICI46,474) as a targeted therapy to treat and prevent breast cancerLetrozole as adjuvant endocrine therapy in postmenopausal women with breast cancerEmerging Selective Estrogen Receptor ModulatorsTamoxifen for the Prevention of Myocardial Infarction in Humans: Preclinical and Early Clinical EvidenceThe effect of estrogens and antiestrogens in rat models of hot flushCurrent concepts in the endocrine therapy of breast cancer: tamoxifen and aromatase inhibitorsEffects of Exemestane Administered for 2 Years Versus Placebo on Bone Mineral Density, Bone Biomarkers, and Plasma Lipids in Patients With Surgically Resected Early Breast CancerComparison of 17β-estradiol structures from x-ray diffraction and solution NMRTamoxifen-treated breast carcinoma patients and the risk of acute myocardial infarction and newly-diagnosed anginaTamoxifen in gynaecologyTreatment with tamoxifen reduces hypoxic–ischemic brain injury in neonatal ratsMeta-analysis of vascular and neoplastic events associated with tamoxifenSelective oestrogen receptor modulators: an updateOestrogens, Oestrogen Receptors and Breast CancerSequential Changes in Serum Triglyceride Levels During Adjuvant Tamoxifen Therapy in Breast Cancer Patients and the Effect of Dose ReductionTamoxifen: a most unlikely pioneering medicineSelective Estrogen-Receptor Modulators — Mechanisms of Action and Application to Clinical PracticeModulation of Estrogen Receptor α Function and Stability by Tamoxifen and a Critical Amino Acid (Asp-538) in Helix 12Update on clinical role of tamoxifenSerum leptin levels are associated with tamoxifen -induced hepatic steatosisFitoestrogênios: posicionamento do Departamento de Endocrinologia Feminina da Sociedade Brasileira de Endocrinologia e Metabologia (SBEM)Effects of Anastrozole on Lipid Metabolism Compared with Tamoxifen in RatsTamoxifen ('Nolvadex'): a reviewEffect of estrogen receptor modulator tamoxifen on blood pressure, plasma renin activity, and renal sodium excretionUse of alternative therapies in menopauseOophorectomy and Tamoxifen Adjuvant Therapy in Premenopausal Vietnamese and Chinese Women With Operable Breast CancerThe evolution of tamoxifen therapy in breast cancer: selective oestrogen-receptor modulators and downregulatorsTissue-specific estrogenic response and molecular mechanismsSelective estrogen receptor modulators (SERMs) and retinoids in breast cancer chemopreventionSERMs Effects on Cardiovascular Risk Factors and DiseaseTamoxifen and toremifene cause impairment of learning and memory function in miceAromatase Inhibitors and Inactivators for Breast Cancer TherapyEfficacy and Economics of Hormonal Therapies for Advanced Breast CancerSelective Estrogen Receptor Modulators as a New Therapeutic Drug Group: Concept to Reality in a DecadeHormonothérapies et cancers du sein : mise au pointEM-652 (SCH57068), a pure SERM having complete antiestrogenic activity in the mammary gland and endometriumChemoprevention with Antiestrogens: The Beginning of the End for Breast CancerThe Past, Present, and Future of Selective Estrogen Receptor ModulationBreast Cancer Prevention with Selective Estrogen Receptor ModulatorsFirst do no harm: extending the debate on the provision of preventive tamoxifenTamoxifen is not detrimental to endothelial function in postmenopausal women with breast cancerEstrogen and Tamoxifen Interplay with T3 in Male Rats: Pharmacologically Distinct Classes of Estrogen Responses Affecting Growth, Bone, and Lipid Metabolism, and Their Relation to Serum GH and IGF-IAlterations in the insulin-like growth factor system during treatment with diethylstilboestrol in patients with metastatic breast cancerSide Effects of Adjuvant Treatment of Breast CancerCloning and Characterization of a Novel Gene That Is Regulated by Estrogen and Is Associated with Mammary Gland Carcinogenesis*Phase I Clinical Trial of Alitretinoin and Tamoxifen in Breast Cancer Patients: Toxicity, Pharmacokinetic, and Biomarker EvaluationsEffects of anti-oestrogens and β-estradiol on calcium uptake by cardiac sarcoplasmic reticulumTamoxifen inhibits nitrotyrosine formation after reversible middle cerebral artery occlusion in the ratHormone Replacement Therapy and Fractures in Older AdultsTamoxifen for early breast cancerMenopausal Health after Breast CancerReferencesPure selective estrogen receptor modulators, new molecules having absolute cell specificity ranging from pure antiestrogenic to complete estrogen-like activitiesHormonoterapia con tamoxifeno y el médico de familiaEndometrial protection from tamoxifen-stimulated changes by a levonorgestrel-releasing intrauterine system: a randomised controlled trialSafety and Efficacy Results of a Randomized Trial Comparing Adjuvant Toremifene and Tamoxifen in Postmenopausal Patients With Node-Positive Breast CancerPrevention of bone loss by EM-800 and raloxifene in the ovariectomized ratTamoxifen: a personal retrospectiveTamoxifen-induced severe hypertriglyceridemia and pancreatitisSelective Estrogen Receptor Modulators in Reproductive Medicine and BiologyEffects of high dose raloxifene in selected patients with advanced breast carcinomaModulation of Estrogen Receptor-α Transcriptional Activity by the Coactivator PGC-1Salubrious effect of vitamin C and vitamin E on tamoxifen-treated women in breast cancer with reference to plasma lipid and lipoprotein levelsClinical development of estrogen modulators for breast cancer chemoprevention in premenopausal vs. postmenopausal womenOverview of Randomized Trials of Systemic Adjuvant TherapyTamoxifen and Other Antiestrogens in Prevention and Therapy of Breast CancerSurgical Oncology Forum: Tamoxifen for the Prevention of Breast Cancer in the High-Risk WomanMolecular Pharmacology of Estrogen and Progesterone ReceptorsAlternative Therapies to Hormone Replacement TherapySelective Estrogen Receptor Modulators (SERMs): A First Step in the Development of Perfect Hormone Replacement Therapy RegimenSelective oestrogen receptor modulators (SERMs)Selective oestrogen receptor modulationSelective oestrogen receptor modulationClomiphene-Induced Severe Hypertriglyceridemia and PancreatitisSerum homocysteine levels in postmenopausal breast cancer patients treated with tamoxifenThe Molecular Pharmacology of SERMsSelected Hormonal Agents in GynecologyRaloxifene, a New Selective Estrogen Receptor ModulatorTamoxifen, Raloxifene, and the Prevention of Breast Cancer*Selective Estrogen Receptor Modulators: Clinical Spectrum*Effect of Tamoxifen on Sexual Functioning in Patients With Breast CancerEM-652 (SCH 57068), a third generation SERM acting as pure antiestrogen in the mammary gland and endometriumTamoxifen Effects on Menopause-Associated Risk Factors and SymptomsSelective estrogen receptor modulators: Women's panacea for the next millennium?Current controversies in breast cancer managementEffect of the potent aromatase inhibitor fadrozole hydrochloride (CGS 16949A) in postmenopausal women with breast carcinomaChemoprevention and Heritable Cancer RiskPharmacology and Use of Antiestrogens in Treatment and Chemoprevention of Breast CancerDevelopment of a New Prevention Maintenance Therapy for Postmenopausal WomenCardiovascular Systemp53 expression in breast and endometrium during estrogen and tamoxifen treatment of surgically postmenopausal cynomolgus macaquesPrevention and Treatment of Osteoporosis in the ElderlyEffect of tamoxifen on cholesterol synthesis in HepG2 cells and cultured rat hepatocytesThe effect of estrogens and antiestrogens in a rat model for hot flushSupplementation with Isoflavonoid Phytoestrogens Does Not Alter Serum Lipid Concentrations: A Randomized Controlled Trial in HumansDRUGS CAUSING DYSLIPOPROTEINEMIATamoxifen for early breast cancer: an overview of the randomised trialsPrevention of development of dimethylbenz(a)anthracene (DMBA)-induced mammary tumors in the rat by the new nonsteroidal antiestrogen EM-800 (SCH57050)The effect of tamoxifen and transdermal 17β-estradiol on cerebral arterial vessels: A randomized controlled studyHormone replacement therapy and nonhormonal control of menopausal symptoms in breast cancer survivorsBlood chemistry profiles in menopausal women administered tamoxifen for breast cancerRecent Advances in Understanding the Molecular Mechanisms of Tamoxifen ActionTissue-Specific Estrogens — The Promise for the FutureA Partial Estrogen Receptor Agonist With Strong Antiatherogenic Properties Without Noticeable Effect on Reproductive Tissue in Cholesterol-Fed Female and Male RabbitsCombined Effects of Dehydroepiandrosterone and EM-800 on Bone Mass, Serum Lipids, and the Development of Dimethylbenz(A)Anthracene-Induced Mammary Carcinoma in the Rat*Preliminary study of cardiac accumulation of F-18 fluorotamoxifen in patients with breast cancerDissection of the Molecular Mechanism of Action of GW5638, a Novel Estrogen Receptor Ligand, Provides Insights into the Role of Estrogen Receptor in Bone*Abnormal vaginal bleeding from endometrial polyps in a woman receiving tamoxifen therapy for breast cancer: Report of a caseA Study of the Effects of Tamoxifen in the Frail Elderly: Difficulties Encountered in Nursing Home ResearchMolecular mechanisms and future uses of antiestrogensHormone replacement: therapeutic strategies in the treatment of Alzheimer's disease and ageing-related cognitive disordersCharacterization of the "Estrogenicity" of tamoxifen and raloxifene in HepG2 cells: Regulation of gene expression from an ERE controlled reporter vector versus regulation of the endogenous SHBG and PS2 genesGuidelines for systemic therapy of early stage breast cancerESTROGENS AND ATHEROSCLEROSISTamoxifen-Induced HypertriglyceridemiaCharacterization of the Ovariectomized Rat Model for the Evaluation of Estrogen Effects on Plasma Cholesterol LevelsLipids and Lipoproteins in WomenPhytoestrogen Effects in Humans Relative to Risk for Cardiovascular Disease, Breast Cancer, Osteoporosis, and Menopausal SymptomsThe Science of NeoplasiaBreast CancerRetroviruses—Human Immunodeficiency VirusAnalysis of the molecular pharmacology of estrogen receptor agonists and antagonists provides insights into the mechanism of action of estrogen in boneTamoxifen: From breast cancer therapy to the design of a postmenopausal prevention maintenance therapyTamoxifen: From breast cancer therapy to the design of a postmenopausal prevention maintenance therapyComparative effects of droloxifene, tamoxifen, and estrogen on bone, serum cholesterol, and uterine histology in the ovariectomized rat modelTissue selective action of tamoxifen methiodide, raloxifene and tamoxifen on creatine kinase B activity in vitro and in vivoEffects of tamoxifen on serum lipid and apolipoprotein levels in postmenopausal patients with breast cancerIs it time to develop an optimal endocrine therapy for premenopausal patients with axillary node positive and negative breast cancer?Identification of an Estrogen Response Element Activated by Metabolites of 17β-Estradiol and RaloxifeneA controlled trial of raloxifene (LY139481) HCl: Impact on bone turnover and serum lipid profile in healthy postmenopausal womenTargeted anti-estrogens to treat and prevent diseases in womenBenzopyran selective estrogen receptor modulators (SERMs): Pharmacological effects and structural correlation with raloxifeneAge-related difference in tamoxifen dispositionMembrane Antioxidant-Mediated Cardioprotective Anticarcinogenic Actions of TamoxifenMolecular, Cellular, and Systemic Mechanisms of Antiestrogen ActionChapter 22. Anti-Osteoporosis AgentsClinical Uses of AntiestrogensPrevention of breast cancer with tamoxifen: the Italian study in hysterectomized womenMechanisms of action of endocrine treatment in breast cancerEffects of the antiestrogen tamoxiten on low-density lipoprotein concentrations and oxidation in postmenopausal womenAn Overview of Considerations for the Testing of Tamoxifen as a Preventive for Breast CancerMeta-Analysis of the Effects of Soy Protein Intake on Serum LipidsThe decision to enter a randomized trial of tamoxifen for the prevention of breast cancer in healthy women: An analysis of the tradeoffsMechanisms of action of antiestrogensPlasma levels of the atherogenic amino acid homocysteine in postmenopausal women with breast cancer treated with tamoxifenTamoxifen's role in chemoprevention of breast cancer: An updatePhase I Study of percutaneous 4-hydroxy-tamoxifen with analyses of 4-hydroxy-tamoxifen concentrations in breast cancer and normal breast tissue?Studies on the estrogen receptor in breast cancer? ? 20 years as a target for the treatment and prevention of cancerWhat if tamoxifen (ICI 46,474) had been found to produce rat liver tumors in 1973?Management of Menopausal Symptoms in Breast Cancer PatientsRaloxifene: A selective estrogen receptor modulatorHip FractureTamoxifen and estrogen lower circulating lipoprotein(a) concentrations in healthy postmenopausal women.Hormone therapy in advanced breast carcinoma: present and future trendsSpeculation on the mechanism of action of triphenylethylene antioestrogensTamoxifen decreases lipoprotein(a) in patients with breast cancer3-[4-(1,2-Diphenylbut-1-enyl)phenyl]acrylic Acid: A Non-Steroidal Estrogen with Functional Selectivity for Bone over Uterus in Rats10 The oestrogen receptorTamoxifen: new membrane-mediated mechanisms of action and therapeutic advancesHormone Replacement Therapy in Women with a History of Breast CarcinomaCancer of the Breast, Cervical Cancers, Ovarian Cancers, and Other CancersAntioxidant benefits of tamoxifen therapy for breast cancer?Molecular mechanisms of antiestrogen action in breast cancer[60] Tamoxifen and estrogens as membrane antioxidants: Comparison with cholesterolMedical Oncologists and Risk Management in Breast CancerOverview of U.S. National Cancer Institute (USNCI) Chemoprevention ResearchThe Antioxidant Action of Synthetic Oestrogens Involves Decreased Membrane Fluidity: Relevance to Their Potential Use as Anticancer and Cardioprotective Agents Compared to Tamoxifen?Tamoxifen is A Na + -Antagonistic Inhibitor of Na + /K + -Transporting ATPase from Tumour and Normal CellsRetinoids and tamoxifen in breast cancer chemopreventionEffect of tamoxifen on serum cholesterol and lipoproteins during chemohormonal therapyHow safe is tamoxifen?Evidence for soluble and nuclear site I binding of estrogens in human aortaA current view of tamoxifen for the treatment and prevention of breast cancerTamoxifen and related compounds decrease membrane fluidity in liposomesChemoprevention strategies for the control of cancerA conjugated equine estrogen with differential effects on uterine weight and plasma cholesterol in the ratTamoxifen inhibits lipid peroxidation in cardiac microsomesLong-Term Sequelae from Adjuvant ChemotherapyClinical management of women at increased risk for breast cancer5 Oestrogens and atherosclerotic vascular disease—lipid factorsBreast cancer chemopreventionShould Healthy Women Take Tamoxifen?Tamoxifen: disease prevention or disease substitution?A therapeutic withdrawal can make a strategic advanceNewsThe role of tamoxifen in the treatment and prevention of breast cancerEffects of Tamoxifen on Bone Mineral Density in Postmenopausal Women with Breast CancerTamoxifen — Panacea or Pandora's Box?Tamoxifen in Axillary Node-Negative Breast Cancer: Multisystem Benefits and RisksPromoting Informed Decision Making: Hormone Replacement TherapyBreast Cancer: Side Effects of Tamoxifen and Anastrozole 1 December 1991Volume 115, Issue 11Page: 860-864KeywordsApolipoproteinsBlood pressureCancer preventionCholesterolClinical trial reportingExerciseGlucoseHigh density lipoproteinLow density lipoproteinMedical risk factors Issue Published: 1 December 1991 Copyright & Permissions© 1991 American College of PhysiciansPDF downloadLoading ...